What is the GMMG-CONCEPT trial?

The GMMG-CONCEPT trial is a clinical phase II, multicenter, open-label study which evaluates induction, consolidation, and maintenance treatment with the quadruplet regimen isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma patients (HR MM pts).

In this video:

Dr. Katja Weisel (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) discusses the interim analysis of the GMMG-CONCEPT trial investigating solely high-risk multiple myeloma patients using the Isa-KRd quadruplet treatment. The initial report still shows significantly impaired prognostic outcomes. The Addition of CD38 monoclonal antibodies to standard-of-care regimens significantly improved response rates and depth of response in newly diagnosed and relapsed or refractory myeloma patients. 

Conclusion:

The overall safety profile of Isa-KRd is expected and consistent with previous reports. The study is ongoing, with patients continuing to be recruited.

Clinical trial information: NCT03104842.


KATJA WEISEL, MD

Dr. Katja Weisel is the Deputy Clinic Director and Senior Physician at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Visit Dr. Katja Weisel’s full biography.

 

Previous Post
KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma
Next Post
Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma patients not undergoing autologous stem cell transplant: The phase III TOURMALINE-MM4 trial

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.